Cortactin表达与结肠直肠癌肿瘤出芽的相关研究

doi:10.16139/j.1007-9610.2018.05.010

外科理论与实践 ›› 2018, Vol. 23 ›› Issue (05): 425-429.doi: 10.16139/j.1007-9610.2018.05.010

Cortactin表达与结肠直肠癌肿瘤出芽的相关研究

刘坤^a, 罗方秀^b, 方旭前^b, 施毅卿^a, 蒋奕玫^a, 陈培战^c, 赵任^a

上海交通大学医学院附属瑞金医院北院 a. 普外科,b. 病理科,c. 临床研究中心,上海 201801

收稿日期:2018-07-23 出版日期:2018-09-25 发布日期:2020-07-25
通讯作者: 赵任,E-mail: zhaorensurgeon@aliyun.com
基金资助:
上海市卫生和计划生育委员会青年支持项目（20144Y0123）; 上海市卫生和计划生育委员会重点课题项目（201540026）

Relationship between Cortactin expression level and tumor budding in colorectal cancer

LIU Kun^a, LUO Fangxiu^b, FANG Xuqian^b, SHI Yiqing^a, JIANG Yimei^a, CHEN Peizhan^c, ZHAO Ren^a

a. Department of General Surgery, b. Department of Pathology, c. Clinical Research Center, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China

Received:2018-07-23 Online:2018-09-25 Published:2020-07-25

摘要/Abstract

摘要： 目的: 分析皮层蛋白Cortactin在肿瘤组织的表达水平和肿瘤出芽程度与结肠直肠癌特征的相关关系。方法: 检测97例结肠直肠癌病人癌组织Cortactin的表达水平和肿瘤出芽程度,分析其与病人临床特征的相关性。结果: Cortactin表达水平与结肠直肠癌病人T分期（P=0.017）和N分期（P<0.001）显著相关。结肠直肠癌Cortactin表达水平较高的病人年龄较小（P=0.043）。肿瘤出芽程度与病人T分期（P=0.031）、血浆CEA水平（P=0.038）以及结肠直肠癌高危因素（P=0.008）显著相关。Cortactin表达与结肠直肠癌肿瘤出芽程度显著相关（P=0.011）。结论: Cortactin表达水平与结肠直肠癌出芽显著相关,提示Cortactin可能促进结肠直肠癌细胞出芽、恶性进展和预后不良。

关键词: 结肠直肠癌, Cortactin, 肿瘤出芽

Abstract: Objective To evaluate Cortactin expression level in the patients with colorectal cancer(CRC) and tumor budding related with the clinical characteristics. Methods The expression of Cortactin and tumor budding levels were detected in 97 CRC patients and the correlations of Cortactin and tumor budding with clinical characteristics were determined. Results Cortactin expression level was significantly related with T stage(P=0.017) and N stage(P<; 0.001) of CRC patients. The patients with higher Cortactin expression level were younger than those with lower Cortactin expression (P=0.043). The tumor budding level was significantly related with T stage (P=0.031), plasma CEA level (P=0.038) and the risk factors of CRC (P=0.008). There was relationship between Cortactin level and tumor budding level in patients with CRC(P=0.011). Conclusions Cortactin expression would be related significantly with the tumor budding of CRC patients. Higher expression of Cortactin suggests the patients poorer prognostic by the mechanism that Cortactin promotes tumor budding and progression of CRC.

Key words: Colorectal cancer, Cortactin, Tumor budding

中图分类号:

刘坤, 罗方秀, 方旭前, 施毅卿, 蒋奕玫, 陈培战, 赵任. Cortactin表达与结肠直肠癌肿瘤出芽的相关研究[J]. 外科理论与实践, 2018, 23(05): 425-429.

LIU Kun, LUO Fangxiu, FANG Xuqian, SHI Yiqing, JIANG Yimei, CHEN Peizhan, ZHAO Ren. Relationship between Cortactin expression level and tumor budding in colorectal cancer[J]. Journal of Surgery Concepts & Practice, 2018, 23(05): 425-429.

参考文献

[1] van Wyk HC, Park JH, Edwards J, et al. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer[J]. Br J Cancer,2016,115(2):156-163.
[2] Wu H, Reynolds AB, Kanner SB, et al.Identification and characterization of a novel cytoskeleton-associated pp60src substrate[J]. Mol Cell Biol,1991,11(10):5113-5124.
[3] Cai JH, Zhao R, Zhu JW, et al.Expression of cortactin correlates with a poor prognosis in patients with stages Ⅱ-Ⅲ colorectal adenocarcinoma[J]. J Gastrointest Surg,2010,14(8):1248-1257.
[4] 朱建伟, 陆毅样, 赵任, 等. 皮层蛋白氨基端同源性多肽分子对大肠癌细胞迁移、内吞能力及侵袭性的抑制[J]. 世界华人消化杂志,2009,17(32):3302-3306.
[5] Edge SB, Byrd DR, Compton CC, et al.AJCC Cancer staging manual[M]. 7th ed. New York:Springer,2010.
[6] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[7] Wang R, Wang MJ, Ping J.Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: A population-based cohort study of SEER 9 registries data(1988-2011)[J]. Medicine (Baltimore),2015,94(35):e1402.
[8] Graham RP, Vierkant RA, Tillmans LS, et al.Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort[J]. Am J Surg Pathol,2015,39(10):1340-1346.
[9] Caie PD, Turnbull AK, Farrington SM, et al.Quantification of tumour budding, lymphatic vessel density and invasion through image analysis in colorectal cancer[J]. J Transl Med,2014,12:156-168.
[10] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31.
[11] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31.
[12] Pollard TD, Borisy GG.Cellular motility driven by assembly and disassembly of actin filaments[J]. Cell,2003, 112(4):453-465.
[13] Bryce NS, Clark ES, Leysath JL, et al.Cortactin promotes cell motility by enhancing lamellipodial persistence[J]. Curr Biol,2005,15(14):1276-1285.
[14] Mueller SC, Yeh Y, Chen WT.Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells[J]. J Cell Biol,1992,119(5):1309-1325.
[15] Mizutani K, Miki H, He H, et al.Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts[J]. Cancer Res,2002,62(3):669-674.
[16] Zhang X, Liu K, Zhang T, et al.Cortactin promotes co-lorectal cancer cell proliferation by activating the EGFR-MAPK pathway[J]. Oncotarget,2017,8(1):1541-1554.
[17] Prall F, Nizze H, Barten M.Tumour budding as prognostic factor in stage Ⅰ/Ⅱ colorectal carcinoma[J]. Histopa-thology,2005,47(1):17-24.
[18] Prall F, Weirich V, Ostwald C.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC) gene[J]. Histopa-thology,2007,50(3):318-330.
[19] Jass JR, Barker M, Fraser L, et al.APC mutation and tumour budding in colorectal cancer[J]. J Clin Pathol,2003,56(1):69-73.
[20] Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, et al.Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma[J]. Hum Pathol,2012,43(7):1094-102.
[21] Brabletz T, Hlubek F, Spaderna S, et al.Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin[J]. Cells Tissues Organs,2005,179(1-2):56-65.
[22] Markl B, Hardt J, Franz S, et al.Tumor budding, uPA, and PAI-1 in colorectal cancer: update of a prospective study[J]. Gastroenterol Res Pract,2017,2017:6504960.

Cortactin表达与结肠直肠癌肿瘤出芽的相关研究

Relationship between Cortactin expression level and tumor budding in colorectal cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[2]	刘诗光, 赵敬坤, 陆爱国, 毛志海. 趋化因子CXCL5和程序性死亡配体 1在结肠直肠癌组织的表达与病人预后的关系[J]. 外科理论与实践, 2021, 26(6): 543-549.
[3]	张华, 陆炜, 杨承翌, 项明洁. 血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[4]	杨盈赤, 宋建宁, 张忠涛. 中国腹腔镜结肠直肠手术的回顾与展望——基于手术病例登记研究和数据库建立的思考[J]. 外科理论与实践, 2021, 26(04): 277-280.
[5]	顾晋. 局部晚期结肠直肠癌治疗和联合脏器切除[J]. 外科理论与实践, 2021, 26(04): 290-296.
[6]	吴春晓, 龚杨明, 顾凯, 庞怡, 鲍萍萍, 王春芳, 施亮, 向詠梅, 窦剑明, 付晨, 施燕. 2016年上海市结肠直肠癌发病和死亡情况与2002—2016年间的变化趋势分析[J]. 外科理论与实践, 2021, 26(04): 325-335.
[7]	蔡三军. 结肠直肠癌诊治的思考[J]. 外科理论与实践, 2021, 26(04): 297-299.
[8]	张弢, 叶枫, 赵任. 结肠直肠癌的微创手术——在工具和价值间的不断平衡优化[J]. 外科理论与实践, 2021, 26(04): 300-304.
[9]	杨飖, 傅传刚. NOSES在结肠直肠癌手术中的应用现状与展望[J]. 外科理论与实践, 2021, 26(04): 305-311.
[10]	王常刚, 刘坤, 冯浩然, 蒋奕玫, 施毅卿, 陈献则, 宋子甲, 李军, 李佑, 蔡东莉, 赵任. 结肠直肠癌B7S1表达与免疫浸润的关系[J]. 外科理论与实践, 2021, 26(04): 336-342.
[11]	茅届齐, 徐多刚, 张米粒, 肖蕴誉, 明旭, 李雨哲, 曹灿, 于亮, 李继坤. 结肠直肠癌病人D-二聚体升高的研究[J]. 外科理论与实践, 2021, 26(04): 361-366.
[12]	程国柱, 蔡国响. 结肠直肠癌腹膜转移的腹腔药物治疗研究[J]. 外科理论与实践, 2021, 26(01): 34-37.
[13]	林松斌, 冯青阳, 许剑民. KRAS基因突变类型预测结肠直肠癌根治术后异时性远处转移[J]. 外科理论与实践, 2021, 26(01): 66-71.
[14]	关天培, 雷子颖, 崔书中. 结肠直肠癌腹膜转移防治临床研究[J]. 外科理论与实践, 2021, 26(01): 7-10.
[15]	邹兴, 赵敬坤, 宗雅萍, 陆爱国. 腹腔镜结肠直肠癌手术吻合口出血的防治[J]. 外科理论与实践, 2021, 26(01): 87-91.